+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Cancer Monoclonal Antibodies Global Market Report 2022: By Monoclonal, By Application, By End-User

  • PDF Icon

    Report

  • 400 Pages
  • March 2022
  • Region: Global
  • The Business Research Company
  • ID: 5553674
Cancer Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global cancer monoclonal antibodies (mabs) market.



This report focuses on cancer monoclonal antibodies (mabs) market which is experiencing strong growth. The report gives a guide to the cancer monoclonal antibodies (mabs) market which will be shaping and changing our lives over the next ten years and beyond, including the markets response to the challenge of the global pandemic.

Reasons to Purchase


  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies
  • Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates
  • Create regional and country strategies on the basis of local data and analysis
  • Identify growth segments for investment
  • Outperform competitors using forecast data and the drivers and trends shaping the market
  • Understand customers based on the latest market research findings
  • Benchmark performance against key competitors
  • Utilize the relationships between key data sets for superior strategizing
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Description:


Where is the largest and fastest growing market for the cancer monoclonal antibodies (mabs)? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Cancer Monoclonal Antibodies (mAbs) market global report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider cancer monoclonal antibodies (mabs) market, and compares it with other markets.

  • The market characteristics section of the report defines and explains the market
  • The market size section gives the market size ($b) covering both the historic growth of the market, the influence of the COVID-19 virus and forecasting its growth
  • Market segmentations break down market into sub markets
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers
  • The cancer monoclonal antibodies (mabs) market section of the report gives context. It compares the cancer monoclonal antibodies (mabs) market with other segments of the cancer monoclonal antibodies (mabs) market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, cancer monoclonal antibodies (mabs) indicators comparison

Scope


Markets Covered:


1) By Monoclonal Antibody Therapies: Bevacizumab (Avastin); Rituximab (Rituxan); Trastuzumab (Herceptin); Cetuximab (Erbitux); Panitumumab (Vectibix); Others
2) By Application: Breast Cancer; Blood Cancer; Liver Cancer; Brain Cancer; Colorectal Cancer; Others
3) By End User: Hospitals And Clinics; Research Laboratories; Pharmacies; Others

Companies Mentioned: Amgen; Bristol Myers Squibb Company; Eli Lilly and Company; F.Hoffmann-La Roche Ltd; Genmab AS

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Frequently Asked Questions about the Global Cancer Monoclonal Antibodies Market

What is the estimated value of the Global Cancer Monoclonal Antibodies Market?

The Global Cancer Monoclonal Antibodies Market was estimated to be valued at $56 billion in 2022.

What is the growth rate of the Global Cancer Monoclonal Antibodies Market?

The growth rate of the Global Cancer Monoclonal Antibodies Market is 11.4%, with an estimated value of $86.23 billion by 2026.

What is the forecasted size of the Global Cancer Monoclonal Antibodies Market?

The Global Cancer Monoclonal Antibodies Market is estimated to be worth $86.23 billion by 2026.

Who are the key companies in the Global Cancer Monoclonal Antibodies Market?

Key companies in the Global Cancer Monoclonal Antibodies Market include Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F.Hoffmann, La Roche Ltd., Genmab AS, GlaxoSmithKline, Johnson & Johnson and Merck & Co..

Table of Contents

1. Executive Summary2. Cancer Monoclonal Antibodies Market Characteristics3. Cancer Monoclonal Antibodies Market Trends And Strategies4. Impact Of COVID-19 On Cancer Monoclonal Antibodies
5. Cancer Monoclonal Antibodies Market Size And Growth
5.1. Global Cancer Monoclonal Antibodies Historic Market, 2016-2021, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Cancer Monoclonal Antibodies Forecast Market, 2021-2026F, 2031F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Cancer Monoclonal Antibodies Market Segmentation
6.1. Global Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Bevacizumab (Avastin)
  • Rituximab (Rituxan)
  • Trastuzumab (Herceptin)
  • Cetuximab (Erbitux)
  • Panitumumab (Vectibix)
  • Others
6.2. Global Cancer Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain Cancer
  • Colorectal Cancer
  • Others
6.3. Global Cancer Monoclonal Antibodies Market, Segmentation By End User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Hospitals and Clinics
  • Research Laboratories
  • Pharmacies
  • Others

7. Cancer Monoclonal Antibodies Market Regional And Country Analysis
7.1. Global Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
7.2. Global Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
8. Asia-Pacific Cancer Monoclonal Antibodies Market
8.1. Asia-Pacific Cancer Monoclonal Antibodies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
9. China Cancer Monoclonal Antibodies Market
9.1. China Cancer Monoclonal Antibodies Market Overview
9.2. China Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion
10. India Cancer Monoclonal Antibodies Market
10.1. India Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
11. Japan Cancer Monoclonal Antibodies Market
11.1. Japan Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
12. Australia Cancer Monoclonal Antibodies Market
12.1. Australia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
13. Indonesia Cancer Monoclonal Antibodies Market
13.1. Indonesia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
14. South Korea Cancer Monoclonal Antibodies Market
14.1. South Korea Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
15. Western Europe Cancer Monoclonal Antibodies Market
15.1. Western Europe Cancer Monoclonal Antibodies Market Overview
15.2. Western Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
16. UK Cancer Monoclonal Antibodies Market
16.1. UK Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
17. Germany Cancer Monoclonal Antibodies Market
17.1. Germany Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
18. France Cancer Monoclonal Antibodies Market
18.3. France Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
19. Eastern Europe Cancer Monoclonal Antibodies Market
19.1. Eastern Europe Cancer Monoclonal Antibodies Market Overview
19.2. Eastern Europe Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
20. Russia Cancer Monoclonal Antibodies Market
20.1. Russia Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
21. North America Cancer Monoclonal Antibodies Market
21.1. North America Cancer Monoclonal Antibodies Market Overview
21.2. North America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
22. USA Cancer Monoclonal Antibodies Market
22.1. USA Cancer Monoclonal Antibodies Market Overview
22.2. USA Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
23. South America Cancer Monoclonal Antibodies Market
23.1. South America Cancer Monoclonal Antibodies Market Overview
23.2. South America Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
24. Brazil Cancer Monoclonal Antibodies Market
24.1. Brazil Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
25. Middle East Cancer Monoclonal Antibodies Market
25.1. Middle East Cancer Monoclonal Antibodies Market Overview
25.2. Middle East Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
26. Africa Cancer Monoclonal Antibodies Market
26.1. Africa Cancer Monoclonal Antibodies Market Overview
26.2. Africa Cancer Monoclonal Antibodies Market, Segmentation By Monoclonal Antibody Therapies, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
27. Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles
27.1. Cancer Monoclonal Antibodies Market Competitive Landscape
27.2. Cancer Monoclonal Antibodies Market Company Profiles
27.2.1. Amgen
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Bristol Myers Squibb Company
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Eli Lilly and Company
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. F. Hoffmann-La Roche Ltd
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Genmab AS
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Cancer Monoclonal Antibodies Pipeline Analysis29. Key Mergers And Acquisitions In The Cancer Monoclonal Antibodies Market30. Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis
31. Appendix
31.1. Abbreviations
31.2. Currencies
31.3. Research Inquiries
31.4. About the Publisher
31.5. Copyright And Disclaimer

Executive Summary

Major players in the cancer monoclonal antibodies market are Amgen, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Genmab AS, GlaxoSmithKline, Johnson & Johnson, Novartis AG, Merck & Co. and Spectrum Pharmaceuticals.

The global cancer monoclonal antibodies market is expected to grow from $49.81 billion in 2021 to $56.00 billion in 2022 at a compound annual growth rate (CAGR) of 12.4%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $86.23 billion in 2026 at a CAGR of 11.4%.

The cancer monoclonal antibodies market consists of sales of monoclonal antibodies used for the treatment of cancer and related services by entities (organizations, sole traders and partnerships) that produce monoclonal antibodies for cancer treatment. Monoclonal antibodies are highly specific molecules for cancer cells as they bind to the proteins on their surface and it activates an immune response. The market consists of revenue generated by cancer monoclonal antibodies companies manufacturing cancer monoclonal antibodies drugs.

The main types of monoclonal antibody therapies in cancer monoclonal antibodies are bevacizumab (avastin), rituximab (rituxan), trastuzumab (herceptin), cetuximab (erbitux) and panitumumab (vectibix). Avastin is a medication that helps people with wet age-related macular degeneration (AMD). It can also be employed to treat diabetic eye problem and other retinal issues. It's administered into the eye to assist delay the loss of eyesight caused by certain disorders. The different applications include breast cancer, blood cancer, liver cancer, brain cancer, colorectal cancer, others and involves various sectors such as hospitals and clinics, research laboratories, pharmacies, others.

The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The rise in the number of cancer cases across the globe is likely to contribute to the growth of the cancer monoclonal antibodies market. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the cancer monoclonal antibodies market.

The high costs involved in the development of monoclonal antibodies with advanced techniques act as a major restrain for the market due to the complex production process, expensive biological and chemical materials, and clinical trials, as well as required safety, efficacy, and quality tests. Advanced equipment is required for the large-scale production of monoclonal antibodies that encompass multiple disulfide bonds and post-translational modifications, and this equipment is expensive. Clinical efficacy is usually achieved by injecting large amounts of monoclonal antibodies into the system, which means that large quantities are required to be produced for each treatment, thus increasing the cost. According to The American Journal of Managed Care, the annual price of monoclonal antibody therapies used in oncology and hematology is about $100,000 higher than those used in other disease states. Thus, the high development costs in using these advanced techniques will restrain market growth.

Companies in the cancer monoclonal antibodies market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated with each other as well as academic and research institutions in this market by way of partnerships and in- or out-licensing deals, this trend has been increasing over recent years. For instance, in September 2020, AbbVie and I-Mab entered into a strategic partnership for the development and commercialization of lemzoparlimab (also known as TJC4), which is a monoclonal antibody drug used to treat multiple cancers. In September 2019, IRBM announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies for cancer.

In March 2020, Gilead Sciences, a US-based biopharmaceutical company, announced its decision to acquire Forty Seven for $4.9 billion. This acquisition is expected to strengthen Gilead’s immuno-oncology R&D portfolio with the addition of Forty Seven’s investigational lead product candidate, magrolimab. Magrolimab is a monoclonal antibody in clinical development for the treatment of several cancers. Forty Seven Inc. is a clinical-stage immuno-oncology company that develops therapies targeting cancer immune evasion pathways and specific cell targeting approaches based on technology licensed from Stanford University.

The countries covered in the cancer monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Amgen
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • F.Hoffmann-La Roche Ltd.
  • Genmab AS
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis AG
  • Merck & Co.
  • Spectrum Pharmaceuticals
  • Seattle Genetics
  • Pfizer
  • Sanofi
  • Abbvie
  • Takeda Pharmaceuticals
  • Genentech
  • AstraZeneca
  • Biogen

Methodology

Loading
LOADING...